Tectonic Therapeutic is the latest venture undertaken by Harvard’s serial entrepreneur Timothy Springer, who co-led the series A round.
Tectonic Therapeutic, a US-based biotechnology spinout of Harvard University, has collected $80m in its series A round co-led by Prof Timothy Springer, one of its co-founders and faculty member at Harvard Medical School.
Vida Ventures and Polaris Partners co-led the round, which also attracted EcoR1 Capital.
Founded in 2019, Tectonic is working on G-protein-coupled receptors (GPCR)-targeted therapies. The proteins are a popular drug target due to their involvement in numerous bodily functions but their potential remains mostly untapped due to a range of challenges Tectonic is aiming to tackle.
The spinout was co-founded by serial entrepreneur Springer – whose previous ventures have included Moderna and Editas Medicine – and his colleague Andrew Kruse, professor of biological chemistry and molecular pharmacology.
Springer said: “GPCRs are central to human biology and are the target of approximately 30% of all currently approved drugs.
“However, many GPCRs still remain…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
